+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Acute pulmonary vasodilator response in paediatric and adult pulmonary arterial hypertension: occurrence and prognostic value when comparing three response criteria



Acute pulmonary vasodilator response in paediatric and adult pulmonary arterial hypertension: occurrence and prognostic value when comparing three response criteria



European Heart Journal 32(24): 3137-3146



To assess the occurrence and prognostic value of acute vasodilator response (AVR) in paediatric vs. adult pulmonary arterial hypertension, and idiopathic/hereditary pulmonary arterial hypertension (iPAH/HPAH) vs. pulmonary arterial hypertension associated with congenital heart disease (PAH-CHD) using three different response criteria. Ninety-nine PAH patients underwent AVR testing (37 children, 62 adults; 70 iPAH/HPAH, 29 PAH-CHD). Three response criteria from clinical practice were used to define AVR. The number of responders was evaluated separately in subgroups based on age, diagnosis, and presence of a non-restrictive post-tricuspid shunt. Numbers of responders varied importantly using the different criteria but were always higher in iPAH/HPAH, compared with PAH-CHD. The number of responders did not differ between paediatric and adult iPAH/HPAH. No responders were identified in patients with a post-tricuspid shunt. Acute vasodilator response was associated with improved survival using all three criteria. Low baseline mean right atrial pressure (mRAP) was associated with improved survival in adults (P< 0.001). High baseline mean pulmonary arterial pressure (mPAP)/mean systemic arterial pressure (mSAP) and pulmonary vascular resistance (PVR)/systemic vascular resistance (SVR) were associated with worse survival, statistically independent from age, diagnosis, and the presence of a post-tricuspid shunt. The proportion of patients with AVR highly depends on the used criteria, but did not differ between paediatric and adult iPAH/HPAH. Current response criteria are not suitable for patients with a post-tricuspid shunt. In both children and adults without post-tricuspid shunts, AVR was associated with improved survival independent of the used criteria. Nevertheless, prognostic value in the individual patient was limited. Baseline mRAP showed a good correlation with survival for adult PAH patients, but not for children. High baseline mPAP/mSAP and PVR/SVR was associated with worse prognosis independent from age, diagnosis, or the presence of a post-tricuspid shunt.

(PDF emailed within 0-6 h: $19.90)

Accession: 051363169

Download citation: RISBibTeXText

PMID: 21893489

DOI: 10.1093/eurheartj/ehr282


Related references

Acute vasodilator test in pulmonary arterial hypertension: evaluation of two response criteria. Vascular Pharmacology 43(3): 143-147, 2005

Prognostic value of acute vasodilator response in pulmonary arterial hypertension: beyond the "classic" responders. Journal of Heart and Lung Transplantation 34(3): 312-318, 2015

Acute Vasodilator Response in Pediatric Pulmonary Arterial Hypertension: Current Clinical Practice From the TOPP Registry. Journal of the American College of Cardiology 67(11): 1312-1323, 2016

Effect of sildenafil on the acute pulmonary vasodilator response to inhaled nitric oxide in adults with primary pulmonary hypertension. American Journal of Cardiology 90(6): 677-680, 2002

Inhibition of phosphodiesterase 1 augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs with acute pulmonary hypertension. American Journal of Physiology. Lung Cellular and Molecular Physiology 290(4): L723-L729, 2005

Stimulation of soluble guanylate cyclase attenuates acute pulmonary hypertension and augments the pulmonary vasodilator response to inhaled nitric oxide. FASEB Journal 18(4-5): Abst 688 14, 2004

Reassessment of the effects of vasodilator drugs in primary pulmonary hypertension: guidelines for determining a pulmonary vasodilator response. American Heart Journal 105(1): 119-127, 1983

Soluble guanylate cyclase activator reverses acute pulmonary hypertension and augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs. Circulation 110(15): 2253-2259, 2004

Assessment of the vasodilator response in primary pulmonary hypertension. Comparing prostacyclin and iloprost administered by either infusion or inhalation. European Heart Journal 24(4): 356-365, 2003

Acute pulmonary vasodilator testing with inhaled treprostinil in children with pulmonary arterial hypertension. Pediatric Cardiology 34(4): 1006-1012, 2013

Acute pulmonary vasodilator testing is a critical step in the management of patients with pulmonary arterial hypertension. Zhonghua Jie He He Hu Xi Za Zhi 31(5): 378-380, 2008

Thoracic epidural anesthesia impairs the hemodynamic response to acute pulmonary hypertension by deteriorating right ventricular-pulmonary arterial coupling. Critical Care Medicine 35(1): 222-229, 2006

Acute vasodilator response to vardenafil and clinical outcome in patients with pulmonary hypertension. European Journal of Clinical Pharmacology 71(10): 1165-1173, 2016

Red blood cell distribution width predicts responsiveness of acute pulmonary vasodilator testing in patients with idiopathic pulmonary arterial hypertension. Clinica Chimica Acta; International Journal of Clinical Chemistry 446: 272-276, 2016

Right-heart function related to the results of acute pulmonary vasodilator testing in patients with pulmonary arterial hypertension caused by connective tissue disease. Journal of the American Society of Echocardiography 25(3): 274-279, 2012